The antagonism of β3-adrenoceptor could reduce melanoma growth in vivo by attenuating Treg and myeloid-derived suppressor cell (MDSC) sub-populations in the tumor microenvironment and by increasing the number of NK and CD8 cells [69]. The gene discussed is CD8A; the disease is melanoma.